Current Pharmaceutical DesignCurrent Pharmaceutical DesignCurrent Pharmaceutical Design1381-61281873-4286Bentham Science64572210.2174/0113816128304967240328065809Immunology, Inflammation & AllergyResearch ArticleIn vitro Modified Release Studies on Melatoninergic Fluorinated Phenylalkylamides: Circumventing their Lipophilicity for Oral AdministrationVlachouMarilenainfo@benthamscience.netSiamidiAngelikiinfo@benthamscience.netProtopapaChrystallainfo@benthamscience.netVlachosMichalisinfo@benthamscience.netKloutsouSophiainfo@benthamscience.netDrelioziChrysoula-Christinainfo@benthamscience.netPapanastasiouIoannisinfo@benthamscience.netSection of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences,, National and Kapodistrian University of AthensSection of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of AthensSection of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences,, National and Kapodistrian University of AthensSection of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens1005202430181433144111012025Copyright ©; 2024, Bentham Science Publishers2024Bentham Science Publishershttps://journals.eco-vector.com/1381-6128/article/view/645722

Introduction:In an attempt to circumvent the lipophilicity burden for the oral administration of new potent synthetic melatoninergic fluorine-substituted methoxyphenylalkyl amides, we conducted in vitro modified release studies using carefully selected matrix tablets’ biopolymeric materials in different ratios.

Method:In particular, we sought to attain release profiles of these analogues similar to that of the parent compound, the chronobiotic hormone Melatonin (MLT), and also of the commercially available drug, Circadin®.

Result:It was found that some of these systems, albeit being more lipophilic than MLT, mimic the in vitro release patterns of melatonin and Circadin®.

Conclusion:Moreover, a number of these derivatives were proven suitable for dealing with sleep onset problems, whilst others for dealing with combined sleep onset/sleep maintenance dysfunctions.

Melatoninsynthetic melatoninergic analogueslipophilicitymatrix tabletsin vitro dissolution studiesoral administration.Reppart SM, Weaver DR, Godson C. Melatonin receptors step into the light: Cloning and classification of subtypes. Trends Pharmacol Sci 1996; 17(3): 100-2. doi: 10.1016/0165-6147(96)10005-5 PMID: 8936344Tarocco A, Caroccia N, Morciano G, et al. Melatonin as a master regulator of cell death and inflammation: Molecular mechanisms and clinical implications for newborn care. Cell Death Dis 2019; 10(4): 317. doi: 10.1038/s41419-019-1556-7 PMID: 30962427Jaworek AK, Szepietowski JC, Hałubiec P, Wojas-Pelc A, Jaworek J. Melatonin as an antioxidant and immunomodulator in atopic dermatitis A new look on an old story: A review. Antioxidants 2021; 10(8): 1179. doi: 10.3390/antiox10081179 PMID: 34439427Morgan PJ, Barrett P, Howell HE, Helliwell R. Melatonin receptors: Localization, molecular pharmacology and physiological significance. Neurochem Int 1994; 24(2): 101-46. doi: 10.1016/0197-0186(94)90100-7 PMID: 8161940Tsotinis A, Afroudakis PA, Davidson K, Prashar A, Sugden D. Design, synthesis, and melatoninergic activity of new azido and isothiocyanato-substituted indoles. J Med Chem 2007; 50(25): 6436-40. doi: 10.1021/jm7010723 PMID: 17988084Tsotinis A, Afroudakis PA, Papanastasiou IP, et al. Mapping the melatonin receptor 8. Selective MT2 agonists derived from 5,6‐Dihydroindolo2,1‐aisoquinolines and related systems. ChemMedChem 2022; 17(12): e202200129. doi: 10.1002/cmdc.202200129 PMID: 35478275Vlachou M, Siamidi A, Dedeloudi A, Konstantinidou S, Papanastasiou I. Pineal hormone melatonin as an adjuvant treatment for COVID-19 (Review). Int J Mol Med 2021; 47(4): 47. doi: 10.3892/ijmm.2021.4880 PMID: 33576451Vlachou M, Siamidi A, Anagnostopoulou D, Christodoulou E, Bikiaris ND. Modified release of the pineal hormone melatonin from matrix tablets containing poly(L-lactic acid) and its PLA-co-PEAd and PLA-co-PBAd copolymers. Polymersfpage 2022; 14(8): 1504. doi: 10.3390/polym14081504 PMID: 35458252Kumar A, Agarwal SP, Khanna R. Modified release bi-layered tablet of melatonin using beta-cyclodextrin. Pharmazie 2003; 58(9): 642-4. PMID: 14531461Vlachou M, Siamidi A, Anagnostopoulou D, et al. Potent lipophilic Melatoninergic x-fluoro-y-methoxy substituted phenylalkylamides: Molecular dynamics calculations and in vitro modified release in aqueous media from tablet formulations. Curr Pharm Des 2023; 29(17): 1370-8. doi: 10.2174/1381612829666230607093311 PMID: 37287297Srinivasan V, Pandi-Perumal SR, Trahkt I, et al. Melatonin and melatonergic drugs on sleep: Possible mechanisms of action. Int J Neurosci 2009; 119(6): 821-46. doi: 10.1080/00207450802328607 PMID: 19326288Tsotinis A, Kompogennitaki R, Papanastasiou I, Garratt PJ, Bocianowska A, Sugden D. Fluorine substituted methoxyphenylalkyl amides as potent melatonin receptor agonists. MedChemComm 2019; 10(3): 460-4. doi: 10.1039/C8MD00604K PMID: 31191854Garratt PJ, Travard S, Vonhoff S, Tsotinis A, Sugden D. Mapping the melatonin receptor 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides. J Med Chem 1996; 39(9): 1797-805. doi: 10.1021/jm9508189 PMID: 8627603Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm 2010; 67(3): 217-23. PMID: 20524422Siamidi A, Konstantinou A, Pavlou P, Siamidis I, Vlachou M. Modified release of acetaminophen from matrix tablet formulations: Influence of tablet geometry. Lett Drug Des Discov 2024; 21(3): 568-74. doi: 10.2174/1570180820666221017162352Vlachou M, Siamidi A. Biopolymers, liposomes, and nanofibers as modified peroral drug release formulants in. Nanomat Clin Appl 2020; pp. 249-70. doi: 10.1016/B978-0-12-816705-2.00008-4Siepmann J, Peppas NA. Higuchi equation: Derivation, applications, use and misuse. Int J Pharm 2011; 418(1): 6-12. doi: 10.1016/j.ijpharm.2011.03.051 PMID: 21458553Pharmacopeia US. USP 39-NF34. In the USP Convention. Rockville 2016, pp. 308-309.Greenspan L. Humidity fixed points of binary saturated aqueous solutions. J Res Natl Bur Stand, A Phys Chem 1977; 81A(1): 89. doi: 10.6028/jres.081A.011Khaled A, Abdel-Hamid S, Nasr M, Sammour OA. Fabrication of extended-dissolution divalproex tablets: A green solvent-free granulation technique. Drug Dev Ind Pharm 2020; 46(6): 975-87. doi: 10.1080/03639045.2020.1764023 PMID: 32362159Maclean N, Khadra I, Mann J, et al. Investigating the role of excipients on the physical stability of directly compressed tablets. Int J Pharm X 2022; 4(4): 100106. doi: 10.1016/j.ijpx.2021.100106 PMID: 34977560Siamidi A, Dedeloudi A, Vlachou M. Probing the release of bupropion and naltrexone hydrochloride salts from biopolymeric matrices of diverse chemical structures. Polymersfpage 2021; 13(9): 1456. doi: 10.3390/polym13091456 PMID: 33946250Kalogeropoulou F, Papailiou D, Protopapa C, et al. Design and development of low- and medium-viscosity alginate beads loaded with Pluronic® F-127 nanomicelles. Materialsfpage 2023; 16(13): 4715. doi: 10.3390/ma16134715 PMID: 37445029Suzuki S, Green PG, Bumgarner RE, Dasgupta S, Goddard WA III, Blake GA. Benzene forms hydrogen bonds with water. Science 1992; 257(5072): 942-5. doi: 10.1126/science.257.5072.942 PMID: 17789637Laracuente ML, Yu MH, McHugh KJ. Zero-order drug delivery: State of the art and future prospects. J Control Release 2020; 327: 834-56. doi: 10.1016/j.jconrel.2020.09.020 PMID: 32931897Saurí J, Millán D, Suñé-Negre JM, et al. Quality by Design approach to understand the physicochemical phenomena involved in controlled release of captopril SR matrix tablets. Int J Pharm 2014; 477(1-2): 431-41. doi: 10.1016/j.ijpharm.2014.10.050 PMID: 25445523